Trending Topics

• REMODELing mechanistic trials for kidney disease: a multimodal, tissue-centered approach to understand the renal mechanism of action of semaglutide

• Severe hypertension with thrombotic microangiopathy: The need for pathogenically targeted treatments

• Mineralocorticoid receptor inhibition in parietal epithelial cells prevents focal segmental glomerulosclerosis and crescentic glomerulonephritis

• KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease (CKD)

• Critical role of transcription factor SOX4 in tubular epithelial cell dedifferentiation and fibroblast activation during kidney fibrosis

• Hierarchical clustering uncovered disease patterns and further untangled complexities in immune complex-mediated idiopathic MPGN and C3 glomerulopathy

• From progression to remission: a new paradigm for success in chronic kidney disease

• The relationship between obesity and chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

• REMODELing mechanistic trials for kidney disease: a multimodal, tissue-centered approach to understand the renal mechanism of action of semaglutide

• KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

• SGLT-2 inhibition in pediatric CKD: Advances, challenges, and opportunities

• Preclinical evaluation of antigen-specific B-cell depletion for phospholipase A2 receptor membranous nephropathy with chimeric autoantibody receptor T cells

• Executive summary of the KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease (CKD)

• Population-based estimated glomerular filtration rate distributions and associated health outcomes provide opportunities for early identification of and primary prevention of chronic kidney disease

• Sodium-glucose co-transporter 2 inhibition improves age-dependent kidney microvascular rarefaction

• Kidney disease and heart failure: Recent advances and current challenges: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

• Kidney health for all: Caring for people, protecting the planet

• A single-arm phase 2 trial of an investigational RNA therapeutic to complement factor B sefaxersen for treatment of IgA nephropathy

• The expanding role of complement inhibitors in the treatment of IgA nephropathy

• Green dialysis: Environmentally sustainable care, growth, and innovation: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

• A secondary analysis of the TESTING trial predicted individual patient response to corticosteroid treatment in IgA nephropathy

• Complement inhibitors and B cell–modifying agents for IgA nephropathy—a Kidney Disease: Improving Global Outcomes (KDIGO) commentary

• Finding the etiology of membranoproliferative glomerulonephritis

• Nobel prize–winning Treg cells in autoimmune kidney diseases and transplantation

• Primary hyperoxaluria(s): From trials to real-life data and pipeline therapies

• Multi-omics analyses reveal the pathogenic role of terminal ileum-derived IgA+β7+ cells in IgA nephropathy

• Taking the “unknown” out of CKDu—optimizing approaches to uncover the cause(s) of epidemic-level kidney disease in low- and middle-income settings: a report from the ISN’s International Consortium of CKDu Collaborators (ISN i3C)

• Targeting B cells in immune-mediated kidney diseases: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

• Sodium glucose transporter 2 inhibition maintains kidney antibacterial response by decreasing complement C1q

• Tiny warriors, big impact: Targeted immunotherapy in kidney diseases

• Defining disease modification in IgA nephropathy: Toward a paradigm shift in management

• Randomized trial of twice-weekly versus thrice-weekly hemodiafiltration for initiation of renal replacement therapy

• Mass spectrometry of minimal change disease and focal segmental glomerulosclerosis

• Infliximab for grade III or IV immune checkpoint inhibitor nephritis clinical and translational evidence

• Effect of baseline dialysis and plasma exchange on renal prognosis in patients with antineutrophil cytoplasmic autoantibody–associated vasculitis

• From dialysis to destinations: Safe travel strategies for patients with CKD

• Povetacicept for IgA nephropathy and primary membranous nephropathy

• CKDs at the crossroads: From failures to future therapies

• Complement-mediated kidney diseases: Role of alternative pathway in glomerular inflammation

• Kidney outcomes in ANCA-glomerulonephritis according to induction immunosuppression and histopathology

• Recurrence of C3 glomerulopathy and immune complex–mediated membranoproliferative glomerulonephritis after kidney transplantation: Challenges and opportunities

• Systematic review of efficacy and safety of avacopan in real-world clinical practice

• Current and emerging therapies for C3 glomerulopathy and primary (idiopathic) immune complex membranoproliferative glomerulonephritis

• From evidence to action: Advancing timely implementation of triple therapy in type 2 diabetes mellitus and CKD

• Complement-mediated kidney diseases: Role of alternative pathway in glomerular inflammation

• A FIDELITY analysis on finerenone with SGLT-2i and GLP-1RA in CKD

• The Pathophysiological mechanism of Beni-koji Choleste-Help or puberulic acid–induced kidney injury

• Effect of steroids on anti-nephrin autoantibodies and B cells in minimal change disease

• Managing blood pressure in dialysis patients: A summary of UK clinical practice guideline

• Prospective cohort study of obinutuzumab in rituximab-resistant primary membranous nephropathy

• Prevention of recurrent kidney stones: A CARI guidelines summary

• Enteric Budesonide treatment in IgA nephropathy

• A multicenter randomized clinical trial of dapagliflozin in patients receiving chronic dialysis (The DARE-ESKD-2 Trial)

• Is obinutuzumab the answer to primary membranous nephropathy resistant to rituximab?

• Mortality and practice patterns in the MEXHEMO hemodialysis cohort

• Hidden in the Kidney: Renal-limited thrombotic microangiopathy without hemolysis

• Enteric and controlled-release budesonide in IgA nephropathy: Expanding access while refining evidence

• KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

• Evaluating the Risk of Cardiovascular Events Associated With Different Immunosuppression Treatments for Glomerular Diseases

• A Nationwide Questionnaire Study Evaluated Kidney Injury Associated With Beni-koji Tablets in Japan

• The Effects of Plasma Exchange and Glucocorticoids on Early Kidney Function Among Patients With ANCA-associated Vasculitis in the PEXIVAS Trial

• New Insights Into Mechanisms Underlying Cognitive Impairment in Chronic Kidney Disease

• Differing Sensitivities to Angiotensin Converting Enzyme Inhibition of Kidney Disease Mediated by APOL1 High-risk Variants G1 and G2

• A Genetically Inducible Endothelial Niche Enables Vascularization of Human Kidney Organoids With Multilineage Maturation and Emergence of Renin Expressing Cells

• Targeted Gene Therapy for Rare Genetic Kidney Diseases

• Hair-straightening Cosmetics Containing Glyoxylic Acid Induce Crystalline Nephropathy

• Treatment of Patients with IgA Nephropathy: A Call for a New Paradigm

• Chronic Kidney Disease–Mineral and Bone Disorder: Conclusions From a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

• Female Sex Hormones Inversely Regulate Acute Kidney Disease Susceptibility Throughout Life

• A randomized controlled trial evaluated the efficacy and safety of apixaban for prevention of recurrent thrombosis after thrombectomy of hemodialysis vascular access

• Insights from the BKEVER trial comparing everolimus versus mycophenolate mofetil for BK polyomavirus infection in kidney transplant recipients

• The critical role of endoplasmic reticulum stress and the stimulator of interferon genes (STING) pathway in kidney fibrosis

• Post-hoc analysis of the CARES trial suggests delayed progression of chronic kidney disease in patients with gout during urate-lowering therapy

• The prevention and management of chronic kidney disease among patients with metabolic syndrome

• Activating soluble guanylyl cyclase attenuates ischemic kidney damage

• TRAIL induces podocyte PANoptosis via death receptor 5 in diabetic kidney disease

• Effects of dialysate potassium concentration of 3.0 mmol/l with sodium zirconium cyclosilicate on dialysis-free days versus dialysate potassium concentration of 2.0 mmol/l alone on rates of cardiac arrhythmias in hemodialysis patients with hyperkalemia

• The autoimmune architecture of childhood idiopathic nephrotic syndrome

• Lupus nephritis: Redefining the treatment goals

• International prevalence patterns of low eGFR in adults aged 18-60 without traditional risk factors from a population-based cross-sectional disadvantaged populations eGFR epidemiology (DEGREE) study

• Epigenetic alterations and memory: Key players in the development/progression of chronic kidney disease promoted by acute kidney injury and diabetes

• Treatment of patients with IgA nephropathy: A call for a new paradigm

• A kidney organoid-based readout to assess disease activity in primary and recurrent focal segmental glomerulosclerosis

• Fibroblast growth factor 23 and fibroblast growth factor receptor 4 promote cardiac metabolic remodeling in chronic kidney disease

• Multi-stain deep learning prediction model of treatment response in lupus nephritis based on renal histopathology

• The membrane attack complex drives thrombotic microangiopathy in complement mediated atypical hemolytic uremic syndrome

• The role of sex and gender in acute kidney injury—consensus statements from the 33rd Acute Disease Quality Initiative

• Age- and sex-specific reference values of estimated glomerular filtration rate for European adults

• Melanocortin 5 receptor signaling protects against podocyte injury in proteinuric glomerulopathies

• Designing clinical trials for the treatment of membranous nephropathy in the anti-PLA2R era: Results of a Nephcure membranous nephropathy workshop

• Anti-nephrin autoantibodies in steroid-resistant nephrotic syndrome may inform treatment strategy

• The prevention and management of chronic kidney disease among patients with metabolic syndrome

• Women and kidney health: Conclusions from a Kidney Disease Improving Global Outcomes (KDIGO) Controversies Conference

• Preventing chronic kidney disease and maintaining kidney health: Conclusions from a “Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference”

• Zigakibart demonstrates clinical safety and efficacy in a Phase 1/2 trial of healthy volunteers and patients with IgA nephropathy

• Mitochondrial dysfunction and mitophagy blockade contribute to renal osteodystrophy in chronic kidney disease-mineral bone disorder

• Gene signature-guided drug screening identified narciclasine as a potential therapeutic for interstitial fibrosis of the kidney

• Single-cell analysis of proximal tubular cells with different DNA content reveals functional heterogeneity in the acute kidney injury to chronic kidney disease transition

• Restoration of branched chain amino acid catabolism improves kidney function in preclinical cardiovascular-kidney-metabolic syndrome models

• Renal Pathology Society/International Kidney and Monoclonal Gammopathy Research Group consensus on pathologic definitions and terminology of monoclonal gammopathy–associated kidney lesions

• Quantifying association of early proteinuria and estimated glomerular filtration rate changes with long-term kidney failure in C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis using the United Kingdom RaDaR Registry

• The Mayo MGRS Prediction Tool calculates the risk of finding monoclonal gammopathy of renal significance in a kidney biopsy in patients with monoclonal gammopathy

• Efficacy and safety of finerenone in patients with an acute change in estimated glomerular filtration rate in the prespecified FIDELITY pool analysis

• Randomized, double-blind, placebo-controlled phase 2a study assessing the efficacy and safety of felzartamab for IgA nephropathy

• Insights from ADPedKD, ERKReg and RaDaR registries provide a multi-national perspective on the presentation of childhood autosomal dominant polycystic kidney disease in high- and middle-income countries

• A nationwide register-based cohort study examined the association between preeclampsia in mothers and the risk of kidney disease in their offspring

• Clinical relevance of computationally derived tubular features and their spatial relationships with the interstitial microenvironment in minimal change disease/focal segmental glomerulosclerosis

• The randomized DIALIZE-Outcomes trial evaluated sodium zirconium cyclosilicate in hemodialysis

• A randomized controlled trial of intravenous immunoglobulin vs standard of care for the treatment of chronic active antibody-mediated rejection in kidney transplant recipients

• Kidney hepcidin protects the collecting duct against ferroptosis in ischemia/reperfusion-induced acute kidney injury

• The podocyte gets a pedicure: Tiny nail clippers for podocyte foot processes

• KDIGO 2025 clinical practice guideline for the management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)

• Preventing chronic kidney disease and maintaining kidney health: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

• Randomized, double-blind, placebo-controlled phase 2a study assessing the efficacy and safety of felzartamab for IgA nephropathy

• Patient preferences for kidney failure treatments

• Anti-nephrin antibodies in adult chinese patients with minimal change disease and primary focal segmental glomerulosclerosis

• Artificial intelligence and perspective for rare genetic kidney diseases

• Urinary C-X-C-motif ligand 9 (CXCL9) in immune checkpoint inhibitor–associated acute interstitial nephritis

• The randomized DIALIZE-Outcomes trial evaluated sodium zirconium cyclosilicate in hemodialysis

• A systematic literature review and meta-analysis evaluated modifiable risk factors for the development of BK polyoma virus–associated complications

• Where next for potassium binders in hemodialysis?

• APOL1 kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

• From progression to remission: A new paradigm for success in chronic kidney disease

• KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

• REMODELing mechanistic trials for kidney disease: A multimodal, tissue-centered approach to understand the renal mechanism of action of semaglutide

• KDIGO 2025 clinical practice guideline for the management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)

• Kidney injury and colocalization of complement C3, IgA, and IgG in glomerular immune-complex deposits of patients with IgA nephropathy or IgA vasculitis with nephritis

• The kidney slit diaphragm resembles a fishnet

• Study Design and Baseline Characteristics of ALIGN, a Randomized Controlled Study of Atrasentan in Patients With IgA Nephropathy

• In Defense of Age-based Estimated GFR Thresholds to Define CKD

• Anticomplement Therapies for C3 Glomerulopathy and Immune-Complex Membranoproliferative Glomerulonephritis Recurrence – A Dawn of New Hope

• N-acetylcysteine in Kidney Disease: Molecular Mechanisms, Pharmacokinetics, and Clinical Effectiveness

• Efficacy and Safety of Pegcetacoplan in Kidney Transplant Recipients With Recurrent Complement 3 Glomerulopathy or Primary Immune Complex Membranoproliferative Glomerulonephritis

• Refining Urgent-Start Peritoneal Dialysis: Definitions, Techniques, and Efficacy for Broader Adoption

• Early Versus Late Initiation of Dialysis in CKD Stage 5: Time for a Consensus

• Direct Oral Anticoagulants in Patients With ESRD and Kidney Transplantation

• Urine Protein-to-Creatinine Ratio Remains Informative Despite Nonsteady State Serum Creatinine During Acute Kidney Injury

• Iptacopan reduces proteinuria and stabilizes kidney function in C3 glomerulopathy

• Thrombotic microangiopathy after kidney transplantation: Insights into genetic etiology and clinical outcomes

• Challenges in the diagnosis and management of immune complex-mediated membranoproliferative glomerulonephritis and complement 3 glomerulopathy

• Open-Label, Randomized, Controlled, Crossover Trial on the Effect of Dapagliflozin in Patients With ADPKD Receiving Tolvaptan

• Targeting the Type I Interferon Pathway in Glomerular Kidney Disease: Rationale and Therapeutic Opportunities

• Outcome of Patients Transplanted for C3 Glomerulopathy and Primary Immune Complex-Mediated Membranoproliferative Glomerulonephritis

• Obinutuzumab and ofatumumab are more effective than rituximab in the treatment of membranous nephropathy patients with anti-rituximab antibodies

• Sodium-glucose cotransporter-2 inhibitor in diabetic and nondiabetic renal transplant recipients

• Addition of a loop diuretic to norepinephrine during treatment of hepatorenal syndrome type 1

• Venous thromboembolism prevention in nephrotic syndrome: The role of aspirin, vitamin K antagonists, and direct oral anticoagulants

• Effects of semaglutide on CKD in patients with type 2 diabetes

• The role of mitochondria in diabetic kidney disease and potential therapeutic targets

• Dotinurad treatment for patients with hyperuricemia complicating CKD

• An exosomal mRNA urine test for detection and risk stratification of human kidney transplant rejection

• A targeted-release formulation of budesonide for the treatment of IgA nephropathy patients with severe renal impairment

• Thrombotic microangiopathy after kidney transplantation: Insights into genetic etiology and clinical outcomes

• Efficacy and safety of rituximab in antiglomerular basement membrane disease

• Clinical presentation and outcomes of antineutrophil cytoplasmic autoantibody–negative pauci-immune glomerulonephritis

• Overview of ADPKD in Pregnancy

• The effect of retatrutide on kidney parameters in participants with type 2 diabetes mellitus and/or obesity

• Finerenone and estimated GFR slope in type 2 diabetes and CKD

• Reversible glomerular thrombotic microangiopathy associated with nintedanib in a kidney transplant recipient

• Open-label, randomized, controlled, crossover trial on the effect of dapagliflozin in patients with ADPKD receiving tolvaptan

• Systematic review of the effects of iron on cardiovascular, kidney, and safety outcomes in patients with CKD

• Randomized double-blind placebo-controlled trial of desmopressin for post–kidney biopsy bleeding

• Persistent B cell depletion after rituximab for autoimmune and glomerular diseases: A case series

• Long-term outcome of adult patients with membranous nephropathy treated with rituximab

• Dotinurad treatment for patients with hyperuricemia complicating CKD

• Venous thromboembolism prevention in nephrotic syndrome: The role of aspirin, vitamin K antagonists, and direct oral anticoagulants

• Update on acute tubulointerstitial nephritis: Clinical features, immunologic insights, and diagnostic and treatment approaches

• Optimization of Renin-angiotensin-aldosterone inhibitor therapies for evidence-based indications: A call to action from the cardio-kidney community

• Impact of improved diagnosis and treatment on holistic CKD burden

• Gut microbiome as a risk factor for future CKD

• Furosemide and serum protein-bound uremic toxin concentrations in patients with CKD

• Furosemide, an old friend of nephrologists for the treatment of CKD: Time to rethink the relationship?

• Holistic impact of CKD: A Clinical, economic, and environmental analysis by IMPACT CKD

• Randomized double-blind placebo-controlled trial of desmopressin for post–kidney biopsy bleeding

• A systematic review of treatment for acute interstitial nephritis

• Impact of CKD on female reproductive hormones

• Finerenone and estimated GFR slope in type 2 diabetes and CKD

• Combination cyclophosphamide and rituximab to minimize glucocorticoid use in antineutrophil cytoplasm antibody–associated vasculitis

• Safety of drugs in breastfeeding women with CKD

• The effect of retatrutide on kidney parameters in participants with type 2 diabetes mellitus and/or obesity

• Treatment with avacopan in ANCA–associated vasculitis with kidney involvement

• Low energy diets for obesity and CKD (SLOW-CKD randomized feasibility study)

• Systematic review and network meta-analysis of initial treatments for lupus nephritis

• The double-icodextrin dose randomized controlled trial of a double icodextrin dose for older patients on incremental continuous ambulatory peritoneal dialysis

• Randomized trial of dapagliflozin in patients with nondiabetic stage 4 CKD

• Cardiovascular complications in ADPKD

• Anti-rituximab antibodies occurrence and clinical outcomes in patients with primary membranous nephropathy

• Antiphospholipid syndrome and the kidney

• Steroid avoidance with low-dose tacrolimus is safe and effective in the long-term for kidney transplant recipients

• Reassessing rituximab in membranous nephropathy: Efficacy, limitations, and the path ahead

• A comprehensive framework for kidney function assessment: Summary of the National Institute of Diabetes and Digestive and Kidney Diseases reimagining kidney function assessment workshop

• Community-acquired acute kidney injury and late kidney dysfunction in survivors of COVID-19 hospitalization

• Normothermic kidney perfusion: Current status and future perspectives

• From evidence to action: Advancing timely implementation of triple therapy in type 2 diabetes mellitus and CKD

• Association of British Clinical Diabetologists and UK Kidney Association joint clinical practice guidelines for the pharmacological management of hyperglycemia in adults with type 2 diabetes mellitus and CKD

• Anti-CD38 daratumumab treatment of chronic active antibody-mediated kidney allograft rejection

• Povetacicept for IgA nephropathy and primary membranous nephropathy

• Evaluating sibeprenlimab in IgA nephropathy – rationale and baseline data from the VISIONARY trial

• Novel treatment paradigms: Complement inhibition in antineutrophil cytoplasmic autoantibody vasculitis

• From evidence to action: Advancing timely implementation of triple therapy in type 2 diabetes mellitus and CKD

• Antiphospholipid syndrome and the kidney

• Current and emerging therapies for C3 Glomerulopathy and primary (Idiopathic) immune complex membranoproliferative glomerulonephritis

• CKDs at the crossroads: From failures to future therapies

• Is it time to consider population-based urine dipstick screening for early detection of kidney disease?

• Is there a role for rituximab in FSGS therapy in adults?

• KDIGO 2024 Clinical Practice Guideline for the Management of LUPUS NEPHRITIS

• Glucagon-like Peptide-1 Receptor Signaling Modifies the Extent of Diabetic Kidney Disease Through Dampening the Receptor for Advanced Glycation end Products–induced Inflammation

• Targeted-release Budesonide Modifies Key Pathogenic Biomarkers in Immunoglobulin A Nephropathy: Insights From the NEFIGAN Trial

• Conservative Kidney Management and Kidney Supportive Care: Core Components of Integrated Care for People With Kidney Failure

• IL-22 is Secreted by Proximal Tubule Cells and Regulates DNA Damage Response and Cell Death in Acute Kidney Injury

• Fibroblastic Reticular Cell-derived Exosomes are a Promising Therapeutic Approach for Septic Acute Kidney Injury

• A New Alternative: Inhibiting Complement Activation in Patients With IgA Nephropathy

• Rationale and Design of the Nephrotic Syndrome Study Network (NEPTUNE) Match in Glomerular Diseases: Designing the Right Trial for the Right Patient, Today

• Kidney Allograft Venous Obstruction From Polycystic Kidney Disease

• KDIGO 2024 Clinical Practice Guideline for the Management of LUPUS NEPHRITIS

• Glucagon-like Peptide-1 Receptor Signaling Modifies the Extent of Diabetic Kidney Disease Through Dampening the Receptor for Advanced Glycation end Products-induced Inflammation

• An Antigen-specific Chimeric Autoantibody Receptor NK Cell Strategy for the Elimination of Anti-PLA2R1 and Anti-THSD7A Antibody-secreting Cells

• KDIGO 2024 Clinical Practice Guideline for the Management of Antineutrophil Cytoplasmic Antibody (ANCA) – Associated Vasculitis

• Mind the Gap in Kidney Care: Translating What We Know Into What We Do

• Physiologic Homeostasis After Pig-to-human Kidney Xenotransplantation

• KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease

• Apolipoprotein E is Enriched in Dense Deposits and is a Marker for Dense Deposit Disease in C3 Glomerulopathy

• Conservative Kidney Management and Kidney Supportive Care: Core Components of Integrated Care for People With Kidney Failure

• The 14th International Podocyte Conference 2023: From Podocyte Biology to Glomerular Medicine

• A Neanderthal Haplotype Introgressed Into the Human Genome Confers Protection Against Membranous Nephropathy

• Ibrutinib-associated Focal Segmental Glomerulosclerosis and the Impact of Podocin Mutations in Chronic Lymphocytic Leukemia

• Are Biomarkers in Acute Kidney Injury Ready for Prime Time? The Time is Right for a Second Look

• NELL-1 Associated Membranous Nephropathy Linked to Skin Fairness Cream use – Insights From an Indian Case Series

• Charting New Frontiers in IgA Nephropathy: A Paradigm Shift Toward Precision Medicine and Early Intervention?

• An Unusual Complication of Arteriovenous Fistula

• A Phase 2b, Randomized, Double-blind, Placebo-controlled, Clinical Trial of Atacicept for Treatment of IgA Nephropathy

• Biomarker Blues: Balancing Hope and Hype in Acute Kidney Injury

• Apolipoprotein E is Enriched in Dense Deposits and is a Marker for Dense Deposit Disease in C3 Glomerulopathy

• The 14th International Podocyte Conference 2023: From Podocyte Biology to Glomerular Medicine

• Frailty in Patients on Dialysis

• Kidney Protective Mechanisms of SGLT2 Inhibitors: Evidence for a Hemodynamic Effect

• SGLT2 Inhibitor: 2-way Superstar in Nephrology?

• SGLT2 Inhibitors Act as Metabolic Transducers to Restore Healthy Nutrient Deprivation and Surplus Signaling in the Kidney

• The Glycolytic Enzyme PFKFB3 Drives Kidney Fibrosis Through Promoting Histone Lactylation-mediated NF-κB Family Activation

• Tauroursodeoxycholic Acid Ameliorates Renal Injury Induced by COL4A3 Mutation

• Challenges in the Development of Novel Methodologies for Measuring Glomerular Filtration Rate

• The Role of Complement in Kidney Disease: Conclusions From a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

• Not Too Much, Not Too Little-Just the Right Amount: The Story of YAP in the Podocyte

• Frailty in Patients on Dialysis

• A Genetically Inducible Endothelial Niche Enables Vascularization of Human Kidney Organoids With Multilineage Maturation and Emergence of Renin Expressing Cells

• Prognostic Implications of Unbiased Molecular Categorization in Kidney Disease

• Long-term Impact of Immediate Versus Deferred Antiretroviral Therapy on Kidney Health in People With HIV

• DNA-binding Protein-A Promotes Kidney Ischemia/Reperfusion Injury and Participates in Mitochondrial Function

• Clinical Trial Designs to Assess Treatment Effects on Glomerular Filtration Rate Decline

• MRI Findings of Renal Cortical Hemosiderosis After Cardiac Valve Surgery

• Genome-wide Association Study of Hospitalized Patients and Acute Kidney Injury

• Genomics in the Kidney Transplant Clinic: The Future Standard of Care?

• Visualization of Intracellular ATP Dynamics in Different Nephron Segments Under Pathophysiological Conditions Using the Kidney Slice Culture System

• The CONVINCE Randomized Trial Found Positive Effects on Quality of Life for Patients With Chronic Kidney Disease Treated With Hemodiafiltration

• Environmental Pollution to Kidney Disease: An Updated Review of Current Knowledge and Future Directions

• Lactate: A Missing Link Between Metabolism and Inflammation in CKD Progression?

• Podocyte Density as a Predictor of Long-term Kidney Outcome in Obesity-related Glomerulopathy

• The Unfairness of Fairness Creams: Unveiling the Toxic Impact on Kidneys of Mercury in Beauty Products

• Salvaging Donated Kidneys From Prolonged Warm Ischemia During Ex Vivo Hypothermic Oxygenated Perfusion

• Evaluation of Glomerular Hemodynamic Changes by Sodium-glucose-transporter 2 Inhibition in Type 2 Diabetic Rats Using in Vivo Imaging

• A Randomized, Open-label, Clinical Trial Examined the Effects of Canagliflozin on Albuminuria and eGFR Decline Using an Individual Pre-intervention eGFR Slope

• Deciphering the Kidney Hemodynamic Effects of SGLT2 Inhibition: Translating Insights From Rats to Humans in Type 2 Diabetes

• The role of complement in kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

• Nanotherapeutic kidney cell-specific targeting to ameliorate acute kidney injury

• Pre-transplant Anti-nephrin Antibodies are Specific Predictors of Recurrent Diffuse Podocytopathy in the Kidney Allograft

• An Expert Discussion on the Atypical Hemolytic Uremic Syndrome Nomenclature—Identifying a Road Map to Precision: A Report of a National Kidney Foundation Working Group

• Controversies and Practical Management of Patients With Gout and Chronic Kidney Disease

• Clinical Validation of the Novel Fluorescent Glomerular Filtration Rate Tracer agent Relmapirazin (MB-102)

• Effects of Dialysate Potassium Concentration of 3.0mEq/l wth Sodium Zirconium Cyclosilicate on Dialysis-free Days Versus Dialysate Potassium Concentration of 2.0mEq/l Alone on Rates of Cardiac Arrhythmias in Hemodialysis Patients With Hyperkalemia

• An international, Multi-center Study Evaluated Rituximab Therapy in Childhood Steroid-resistant Nephrotic Syndrome

• Inhibition of Complement Factor C5a or C5aR for Cholesterol Crystal Embolism–related Vascular Thrombosis With Microvascular Injury and its Consequences

• The CONVINCE Randomized Trial Found Positive Effects on Quality of Life for Patients With Chronic Kidney Disease Treated With Hemodiafiltration

• Lupus Nephritis: Redefining the Treatment Goals

• Transfusion-induced HLA sensitization in Wait-list Patients and Kidney Transplant Recipients

• Anti-slit Diaphragm Antibodies on Kidney Biopsy Identify Pediatric Patients With Steroid-resistant Nephrotic Syndrome Responsive to Second-line Immunosuppressants

• Cilastatin, a New Therapeutic Promise for Acute Kidney Injury

• Iohexol Plasma Clearance Measurement Protocol Standardization for Adults: a Consensus Paper of the European Kidney Function Consortium

• Myeloperoxidase-ANCA IgG Induces Different Forms of Small Vessel Vasculitis Based on Type of Synergistic Immune Stimuli

• Evaluation of Non-invasive Biomarkers of Kidney Allograft Rejection in a Prospective Multicenter Unselected Cohort Study (EU-TRAIN)

• A Randomized Phase 2b Trial Examined the Effects of the Glucagon-like Peptide-1 and Glucagon Receptor Agonist Cotadutide on Kidney Outcomes in Patients With Diabetic Kidney Disease

• Novel Treatment Paradigms: Primary IgA Nephropathy

• Kidney Diseases Associated With Inflammatory Bowel Disease: Impact of Chronic Histologic Damage, Treatments, and Outcomes

• C3 Glomerulopathy: Novel Treatment Paradigms

• Framework of Guidelines for Management of CKD in Asia

• Pathologic Spectrum of Kidney Diseases Within Very Elderly Patients Who Underwent Kidney Biopsy

• A Prospective Study on Complement Activation Distinguishes Focal Segmental Glomerulosclerosis From Minimal Change Disease

• “Eculizumab First” in the Management of Posttransplant Thrombotic Microangiopathy

• Prospective Study on Individualized Dose Adjustment of Tolvaptan Based on Urinary Osmolality in Patients With ADPKD

• The Role of Sodium-Glucose Cotransporter-2 Inhibitors in the Treatment Paradigm of CKD in Africa: An African Association of Nephrology Panel Position Paper

• Novel Treatment Paradigms: Primary IgA Nephropathy

• Alkaline Phosphatase and Parathyroid Hormone Levels: International Variation and Associations With Clinical Outcomes in the DOPPS

• A Randomized Controlled Study of Efficacy and Safety of Accelerated Versus Standard Hepatitis B Vaccination in Patients With Advanced CKD

• Clinical Characteristics and Outcomes of NELL1-Associated Membranous Nephropathy

• Complement and Podocytopathies: Do We Have a New Biomarker?

• A Pilot Study on the Safety and Adequacy of a Novel Ecofriendly Hemodialysis Prescription-Green Nephrology

• Prospective Study on Individualized Dose Adjustment of Tolvaptan Based on Urinary Osmolality in Patients With ADPKD

• Barriers to Optimal Kidney Health Among Indigenous Peoples

• Fournier’s Gangrene in a Patient With CKD Without Diabetes Possibly Related to Sodium-Glucose Cotransporter 2 Inhibitor Therapy

• Aversion to a High Salt Taste is Disturbed in Patients With CKD

• Performance Evaluation of an Automated Peritoneal Dialysis Solution Generation System in Patients Using Automated Peritoneal Dialysis

• A Transplant-inclusive Value-based Kidney Care Payment Model

• Real-world Experience With Avacopan in Antineutrophil Cytoplasmic Autoantibody-associated Vasculitis

• What is the Appropriate Dose of Tolvaptan in ADPKD?

• Genetic Diagnosis of Adult Hemodialysis Patients With Unknown Etiology

• WCN’24-1506 Efficacy and Safety of Iptacopan in Patients With IgA Nephropathy: Interim Results From the Phase 3 APPLAUSE-IgAN Study

• Interferon and B-cell Signatures Inform Precision Medicine in Lupus Nephritis

• WCN’24-967 Acute Kidney Injury Due to Adenia Ellenbeckii Poisoning. A Case Report

• Infectious Disease Prophylaxis During and After Immunosuppressive Therapy

• Predictive Factors of Renal Recovery and Progression to End-stage Kidney Disease in Patients With Antineutrophil Cytoplasmic Autoantibody-associated Vasculitis With Severe Kidney Disease

• Nedosiran Safety and Efficacy in PH1: Interim Analysis of PHYOX3

• Obinutuzumab as Initial or Second-line Therapy in Patients With Primary Membranous Nephropathy

• Clinicopathologic Features of IgG4-related Kidney Disease

• Elevated Exposure to Air Pollutants Accelerates Primary Glomerular Disease Progression

• Effects of Once-weekly Semaglutide on Kidney Disease Outcomes by KDIGO Risk Category in the SUSTAIN 6 Trial

• Torque Teno Virus-guided Immunosuppression in Kidney Transplantation: Expanding the Application

• Description and Cross-sectional Analyses of 25,880 Adults and Children in the UK National Registry of Rare Kidney Diseases Cohort

• Thrombotic Microangiopathy in Pregnancy: Current Understanding and Management Strategies

• Key Points in Managing PLA2R-associated Membranous Nephropathy

• Acute Kidney Injury and Hair-straightening Products

• Corticosteroids in Patients With IgA Nephropathy: Is the Lower the Better?

• Certain Red Yeast Rice Supplements in Japan Cause Acute Tubulointerstitial Injury

• Description and Cross-sectional Analyses of 25,880 Adults and Children in the UK National Registry of Rare Kidney Diseases Cohort

• Antinephrin-associated Primary Focal Segmental Glomerulosclerosis Successfully Treated With Plasmapheresis

• Phase 1b/2a Study Assessing the Safety and Efficacy of Felzartamab in Anti-phospholipase A2 Receptor Autoantibody-positive Primary Membranous Nephropathy

• Global aHUS Registry Analysis of Patients Switching to Ravulizumab From Eculizumab

• Biomarkers of Kidney Disease Progression in ADPKD

• Dialysis Discontinuation, Prognosis, and Shared Decision-making

• Avacopan in Anti-neutrophil Cytoplasmic Autoantibodies-associated Vasculitis in a Real-world Setting

• Obinutuzumab as Initial or Second-Line Therapy in Patients With Primary Membranous Nephropathy

• Lower Parathyroid Hormone Levels are Associated With Reduced Fracture Risk in Japanese Patients on Hemodialysis

• A Randomized Controlled Trial Comparing Automated Peritoneal Dialysis and Hemodialysis for Urgent-start Dialysis in ESRD

• Phase 1b/2a Study Assessing the Safety and Efficacy of Felzartamab in Anti-phospholipase A2 Receptor Autoantibody-positive Primary Membranous Nephropathy

• Avacopan in Anti-neutrophil Cytoplasmic Autoantibodies–associated Vasculitis in a Real-world Setting

• N-acetylcysteine in Kidney Disease: Molecular Mechanisms, Pharmacokinetics, and Clinical Effectiveness

• Implementation and Evaluation of a National Multidisciplinary Kidney Genetics Clinic Network Over 10 Years

• Cardioprotective Effect of SGLT2 Inhibitor in Diabetic Kidney Transplant Recipients: A Multicenter Propensity Score Matched Study

• Clinical Characteristics of Nephrin Autoantibody-positive Minimal Change Disease in Older Adults

• Thrombotic Microangiopathy in Pregnancy: Current Understanding and Management Strategies

• Importance of IFT140 in Patients with Polycystic Kidney Disease Without a Family History

• Combination Therapy With Rituximab and Low-dose Cyclophosphamide and Prednisone in Membranous Nephropathy

• Antinephrin-Associated Primary Focal Segmental Glomerulosclerosis Successfully Treated With Plasmapheresis

• Clinicopathologic Features of IgG4-Related Kidney Disease

• Keep Calm and Dialyze On: Debunking the Myths of Peritoneal Dialysis Leaks

• The Role of Urate in Calcium Stone Formation

• Spectrum of Kidney Biopsy Findings Associated With Methamphetamine Use

• Impact of Different Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blocker Resumption Timing on Post Acute Kidney Injury Outcomes

• Imlifidase in Highly Sensitized Kidney Transplant Recipients With a Positive Crossmatch Against a Deceased Donor

• Anticoagulation for the Prevention of Thrombotic Events in Nephrotic Syndrome

• Key Points in Managing PLA2R-associated Membranous Nephropathy

• Global aHUS Registry Analysis of Patients Switching to Ravulizumab From Eculizumab

• Challenges in the Diagnosis and Management of Immune Complex-Mediated Membranoproliferative Glomerulonephritis and Complement 3 Glomerulopathy

• Review of Exercise Interventions to Improve Clinical Outcomes in Nondialysis CKD

• SGLT2-Inhibition in Patients With Alport Syndrome

• Urinary Soluble CD163: A Novel Biomarker Suggests Who Should Receive Glucocorticoids in IgA Nephropathy

• Interference of UACR Measurement by Glycosuria: Clinical Implications When Using SGLT-2 Inhibitors

• Post hoc Analysis suggests People With Type 2 Diabetes treated with Semaglutide experience more stable Kidney Function

• A Novel Direct AMPK Activator Ameliorates Disease Progression in Preclinical Models of ADPKD

• Glucocorticoids for IgA Nephropathy-pro

• First do no Harm: Systemic Glucocorticoids Should not be Used for the Treatment of Progressive IgA Nephropathy

• International Society of Nephrology First Consensus Guidance for Preclinical Animal Studies in Translational Nephrology

• Single Cell Landscape of Parietal Epithelial Cells in Healthy and Diseased States

• Prospective, Randomized, Multicenter Clinical Study Comparing a Self-expanding Covered Stent to PTA for Treatment of AVF Stenosis

• Perspectives on Early Detection of Chronic Kidney Disease: the Facts, the Questions, and a Proposed Framework for 2023 and Beyond

• Podocyte Protease Activated Receptor 1 Stimulation in Mice Produces FSGS Mirroring Human Disease Signaling Events

• IgA Nephropathy and Glucocorticoids – a Limbo Dance?

• Novel MUC1 Variant Identified by Massively Parallel Sequencing Explains Interstitial Kidney Disease in a Large Dutch Family

• Novel Anemia Therapies in Chronic Kidney Disease: Conclusions From a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

• Bio-impedance Spectroscopy Added to a Fluid Management Protocol Does not Improve Preservation of Residual Kidney Function in Incident Hemodialysis Patients in a Randomized Controlled Trial

• Quality of Life: A Crucial Aspect for the Patients, a Neglected Goal in the Treatment of Anemia in Patients with CKD

• IgA Nephropathy: The Lectin Pathway and Implications for Targeted Therapy

• Application of the Banff Human Organ Transplant Panel to Kidney Transplant Biopsies With Features Suspicious for Antibody-mediated Rejection

• Effects of Newer Kidney Protective Agents on Kidney Endpoints Provide Implications for Future Clinical Trials

• Water Implications in Dialysis Therapy, Threats and Opportunities to Reduce Water Consumption: A Call for the Planet

• Peroxiredoxin 1 Aggravates Acute Kidney Injury by Promoting Inflammation Through Mincle/Syk/NF-κB Signaling

• Hypoxia Hits APOL1 in the Kidney

• Novel Mechanisms of Salt-sensitive Hypertension

• The Axolotl Kidney: A Novel Model to Study Kidney Regeneration

• PCSK9 Targets Megalin in the Kidney Proximal Tubule and Aggravates Proteinuria in Nephrotic Syndrome

• Effectiveness of Diuretics and CCBs on Top of RAS Inhibitors on CKD Progression and Mortality

• Green Nephrology: Minimizing the Environmental Impact of Kidney Health Care

• Vitamin D Supplementation in People With Chronic Kidney Disease

• Sodium Glucose Co-transporter 2 Inhibition Increases Epidermal Growth Factor Expression and Improves Outcomes in Patients With Type 2 Diabetes

• Deletion of Protein Tyrosine Phosphatase SHP-1 Restores SUMOylation of Podocin and Reverses the Progression of Diabetic Kidney Disease

• Managing the Symptom Burden Associated With Maintenance Dialysis: Conclusions From a KDIGO Controversies Conference

• A Kidney-centric View of Pre-eclampsia Through the Kidney-placental Bidirectional Lens

• Rare Variants in the Sodium-dependent Phosphate Transporter Gene SLC34A3 Explain Missing Heritability of Urinary Stone Disease

• A Comprehensive Description of Kidney Disease Progression After Acute Kidney Injury From a Prospective, Parallel-group Cohort Study

• One Antigen Closer to Understanding Membranous Nephropathy

• Post Hoc Analysis of the SONAR Trial Indicates That the Endothelin Receptor Antagonist Atrasentan is Associated With Less Pain in Patients With Type 2 Diabetes and Chronic Kidney Disease

• The ASSESS-AKI Study Found Urinary Epidermal Growth Factor is Associated With Reduced Risk of Major Adverse Kidney Events

• Fluid Management Protocols in Hemodialysis Patients Using Bioimpedance Validation: Time to Look Elsewhere?

• Mayo Clinic Consensus Report on Membranous Nephropathy: Proposal for a Novel Classification

• Vitamin D Supplementation in People With Chronic Kidney Disease

• Sodium Glucose Co-transporter 2 Inhibition Increases Epidermal Growth Factor Expression and Improves Outcomes in Patients With Type 2 Diabetes

• Managing the Symptom Burden Associated With Maintenance Dialysis: Conclusions From a Kidney Disease – Improving Global Outcomes (KDIGO) Controversies Conference

• A Kidney-centric View of Pre-eclampsia Through the Kidney-placental Bidirectional Lens

• Rare Variants in the Sodium-dependent Phosphate Transporter Gene SLC34A3 Explain Missing Heritability of Urinary Stone Disease

• A Novel Multi-ancestry Proteome-wide Mendelian Randomization Study Implicates Extracellular Proteins, Tubular Cells, and Fibroblasts in Estimated Glomerular Filtration Rate Regulation

• Glomerular-tubular Crosstalk via Cold Shock Y-box Binding Protein-1 in the Kidney

• Evaluation of the Stopping Angiotensin Converting Enzyme Inhibitor Compared to Angiotensin Receptor Blocker (STOP ACEi Trial) in Advanced and Progressive Chronic Kidney Disease

• Results of a Randomized Double-blind Placebo-controlled Phase 2 Study Propose Iptacopan as an Alternative Complement Pathway Inhibitor for IgA Nephropathy.

• An Introduction to Realist Evaluation and Synthesis for Kidney Research

• Mendelian Randomization for Nephrologists

• Anti-obesity Pharmacotherapy in Adults With Chronic Kidney Disease

• Abnormal Lactate Metabolism is Linked to Albuminuria and Kidney Injury in Diabetic Nephropathy

• Unveiling a New Era With Liquid Chromatography Coupled With Mass Spectrometry to Enhance Parathyroid Hormone Measurement in Patients With Chronic Kidney Disease

• Mayo Clinic Consensus Report on Membranous Nephropathy: Proposal for a Novel Classification

• Targeted-release Budesonide Modifies Key Pathogenic Biomarkers in Immunoglobulin A Nephropathy: Insights From the NEFIGAN Trial

• Valacyclovir-associated Acute Kidney Injury

Shutterstock

• Unmet Needs of CKD in Latin America: A Review from Expert Virtual Working Group

• Impact of Sodium-Glucose Cotransporter-2 Inhibitors on Urolithiasis

• Factor B Mutation in Monozygotic Twins Discordant for Atypical Hemolytic Uremic Syndrome

• Narrative Review of Glycemic Management in People With Diabetes on Peritoneal Dialysis

• Atypical Anti-Glomerular Basement Membrane Disease

• Pregnancy History and Kidney Disease Progression Among Women Enrolled in Cure Glomerulonephropathy

• The Interplay Between Dietary Sodium Intake and Proteinuria in CKD

• An International Survey of Peritoneal Dialysis Exercise Practices and Perceptions

• Managing Hyperkalemia in the Modern Era: A Case-based Approach

• Heterogeneity of Target Antigens in Sarcoidosis-Associated Membranous Nephropathy

• Multiomics Analysis of Plasma Proteomics and Metabolomics of Steroid Resistance in Childhood Nephrotic Syndrome Using a “Patient-Specific” Approach

• Randomized Trial on the Effect of Oral Potassium Chloride Supplementation on the NCC in Healthy Adults

• Long-Term Efficacy and Safety of Rituximab Versus Tacrolimus in Children With Steroid Dependent Nephrotic Syndrome

• Assessing the Accuracy of ChatGPT on Core Questions in Glomerular Disease

• Clinicopathologic Spectrum of Lysozyme-associated Nephropathy

• Managing Hyperkalemia in the Modern Era: A Case-based Approach

• Avacopan in Patients With Rapidly Progressive Glomerulonephritis Requiring Dialysis

• Evidence for Kidney Volume as a Measure of ADPKD Severity “Marches On” in the OVERTURE Study

• Introducing the International Home Dialysis Consortium

• Prescribing Patterns for Sodium-glucose Cotransporter 2 Inhibitors: A Survey of Nephrologists

• Effect of Belimumab on Preventing de Novo Renal Lupus Flares

• Worldwide Exploration of Renal Replacement Outcomes Collaborative in Kidney Disease (WE-ROCK)

• Randomized Controlled Clinical Trial of Treatment With Vitamin K2 on Vascular Calcification in Hemodialysis Patients (Trevasc-HDK)

• Children With Steroid Dependent Nephrotic Syndrome: Rituximab or Tacrolimus? It’s All in the Timing

• Cardiovascular Manifestations and Management in ADPKD

• Targeting the Endothelin A Receptor in IgA Nephropathy

• The Association Between Metabolic Syndrome, Hyperfiltration, and Long-term GFR Decline in the General Population

• Diagnosis of Kidney Diseases of Unknown Etiology Through Biopsy-genetic Analysis

• Donor-derived Cell-free DNA in Biopsy-proven Antibody-mediated Rejection Versus Recurrent IgA Nephropathy After Kidney Transplantation

• Randomized Study of Tenapanor Added to Phosphate Binders for Patients With Refractory Hyperphosphatemia

• Twitter as Educational Tool: A Global Web-based Cross-sectional Study on Social Media Behavior of Nephrologists

• The Phenotypic Spectrum of COL4A3 Heterozygotes

• Residual Kidney Function and Cause-specific Mortality Among Incident Hemodialysis Patients

• Clinical Characteristics and Outcomes of Drug-induced Acute Kidney Injury Cases

• Regional Variation in Hemoglobin Distribution Among Individuals With CKD: the ISN International Network of CKD Cohorts

• Updates on New Therapies for Patients with Chronic Kidney Disease

• Targeting the Endothelin A Receptor in IgA Nephropathy

• Cardiovascular Manifestations and Management in ADPKD

• Randomized Study of Tenapanor Added to Phosphate Binders for Patients With Refractory Hyperphosphatemia

• Non-Fluoroscopic Techniques to Insert a Tunneled Hemodialysis Catheter

• Classifying Hypotonic Hyponatremia by Projected Treatment Effects – A Quantitative 3-Dimensional Framework

• Patient Survival With Extended Home Hemodialysis Compared to In-center Conventional Hemodialysis

• Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy

• Tenapanor as Add-on Treatment for Hyperphosphatemia in Dialysis Patients: Enough Bang for the Buck?

• Exercise-Induced Fluid Retention, Cardiac Volume Overload, and Peripheral Edema in Ultra-Distance Cyclists

• Systematic Review of Cardiovascular Benefits and Safety of Sacubitril-Valsartan in End-Stage Kidney Disease

• Mycophenolate Mofetil and Steroid for Treatment of Patients With IgA Nephropathy

• Iptacopan in Idiopathic Immune Complex–Mediated Membranoproliferative Glomerulonephritis: Protocol of the APPARENT Multicenter, Randomized Phase 3 Study

• Beyond Serology: Is There Still a Value of Kidney Biopsy in Anti-Glomerular Basement Membrane Disease?

• Kidney Diseases Associated with Inflammatory Bowel Disease: Impact of Chronic Histologic Damage, Treatments and Outcomes

• Updates on New Therapies for Patients With CKD

• Novel Treatment Paradigms: Primary IgA Nephropathy

• Impact of Remote Monitoring on Standardized Outcomes in Nephrology-Peritoneal Dialysis